← Back to headlines
Immunic Receives New 'Buy' Rating from Guggenheim on Lead Asset
Immunic has garnered a new 'Buy' rating from Guggenheim, indicating positive analyst sentiment regarding its lead asset.
24 Mar, 15:48 — 24 Mar, 15:48
Sources
Showing 1 of 1 sources
